New eye drug BBC1501 enters first human safety trial for blinding disease

NCT ID NCT05803785

Recruiting now Disease control Sponsor: Benobio Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental drug called BBC1501, given as an injection into the eye, for people with wet age-related macular degeneration (nAMD). The main goal is to check safety and tolerability in 18 volunteers aged 50 and older who have already received standard treatment. Researchers will also look for early signs of benefit, but the primary focus is on whether the drug is safe enough to study further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BBC1501 (an experimental drug injected into the eye)
What this could lead to: If safe and effective, BBC1501 could offer a new treatment option for wet age-related macular degeneration, potentially reducing the need for frequent eye injections.
What could go wrong: This is a very early, small Phase 1 trial with only 18 participants, focused on safety. It is not designed to prove the drug works, and many early-stage drugs fail to show benefit or have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

Benobio Investigational site
NOT_YET_RECRUITING

Sydney, New South Wales, 2000, Australia
Sydney Hospital
RECRUITING

Sydney, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.